Standard BioTools (LAB) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and business model

• Focused on consolidating the life science tools industry with a disciplined, lean operating system inspired by the Toyota Production System.

• Built a diversified portfolio through two acquisitions, reaching $174 million in revenue and maintaining a strong cash position over $300 million as of September 30, with $311M net cash as of Q3'24.

• Targeting high-growth, high-margin markets and leveraging a seasoned management team with over 200 years of combined experience from top life science companies.

• Portfolio structured as a value pyramid: high-margin consumables, instruments, and a strong service business, with a shift toward 80% of future revenue from consumables and services.

• Market conditions in life science tools and biopharma are challenging, with decreased valuations and financing, creating consolidation opportunities.

Acquisition strategy and growth plans

• Rigorous M&A criteria: margin profile, de-risked technologies, clear commercialization path, and value unlock via the business system.

• Plans to pursue 4–6 acquisitions over the next 18–24 months, focusing on assets ready for commercialization and disciplined deal-making.

• Organic growth and gross margin expansion are priorities, with M&A intended to accelerate future growth rather than being required for profitability.

• The M&A pipeline is disciplined, focusing on high-margin, de-risked technologies with clear commercialization paths and synergies.

• Forward-looking statements highlight risks related to M&A integration, market conditions, and execution, with financial targets for 2025 and 2026 focused on revenue growth, margin expansion, and cash flow improvement.

Operational achievements and financial discipline

• Achieved a 32% improvement in adjusted EBITDA loss and a 20% increase in on-time delivery to 98%.

• Non-GAAP gross margin improved to 57% in Q3 2024, up 520 bps YoY, driven by a favorable product mix and operational improvements.

• Non-GAAP operating expenses reduced by 24% YoY in Q3 2024, with $80M in merger cost synergies operationalized ahead of plan.

• Adjusted EBITDA improved by 50% YoY in Q3 2024, with a $14M reduction in losses, reflecting ongoing cost discipline and integration benefits.

• Cash and equivalents stood at $368M at the end of Q3 2024, with a 29% reduction in adjusted cash burn, supporting continued growth initiatives and a runway to positive cash flow.